Streetbeat News

Products Services

XOS

Xos Inc has announced the delivery of 100% battery-electric stepvans to several parcel and delivery independent service providers in Tennessee and California.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 12:49 pm

CYTO

Altamira Therapeutics has reported additional efficacy outcomes from its Bentrio clinical trial in seasonal allergic rhinitis. The NASAR clinical trial demonstrated the efficacy and tolerability of Bentrio nasal spray in treating seasonal allergic rhinitis, meeting both primary and secondary efficacy endpoints. The treatment also showed a statistically significant improvement in health-related quality of life secondary efficacy endpoint. The efficacy was demonstrated from the first day of the 2-week treatment period and across allergy symptoms and functional problems. Bentrio treatment was associated with a reduced need for relief medication.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 12:49 pm

HEPA

Hepion Pharmaceuticals' drug, Rencofilstat, has shown positive outcomes in a translational study on Idiopathic Pulmonary Fibrosis (IPF). Proteomics analysis revealed that Rencofilstat improved aberrant protein profiles in IPF tissues. The drug showed superior effects alone and in combination with pirfenidone and nintedanib.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 12:47 pm

BMY

Bristol Myers Squibb (BMY) plans to double its number of registrational assets from six to twelve over the next 18 months. The company also stated that it has over 25 indication expansion opportunities on the horizon.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 12:40 pm

EVOK

Evoke Pharma has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application related to Gimoti, an FDA-approved nasal formulation of Metoclopramide. The patent will cover the intranasal pharmaceutical composition.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 12:40 pm

DRTS

Alpha Tau Medical has treated a patient with advanced inoperable pancreatic cancer using its Alpha-radiation Cancer Therapy Alpha DaRT in a clinical trial at Hadassah Medical Center in Israel. The trial is designed for a broad range of solid tumor patients who do not qualify for other existing trials or do not have other treatment options.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 12:38 pm

NBIX

The FDA has accepted to review Neurocrine Biosciences' New Drug Application for Ingrezza (Valbenazine) oral granules. The Prescription Drug User Fee Act target action date is April 30, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 12:36 pm

RSLS

Reshape Lifesciences has been awarded a $331,541 Small Business Innovation Research Grant to develop its Diabetes Bloc-Stim Neuromodulation device. The device uses the company's Vagus Nerve Block technology in combination with Vagus Nerve Stimulation for the treatment of Type 2 Diabetes.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 12:34 pm

LYT

Lytus Technologies has established Lytus Studios in the U.S. to provide content creation and technology services. The studio will offer creative services and technology infrastructure for various industries including film, video, series, commercials, events, corporate, and digital.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 12:28 pm